ArticleHuman brain mapping2026
Multimodel Diffusion MRI Signatures in Atypical Parkinsonian Disorders.
Article in Human brain mapping, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Distinguishing atypical parkinsonian disorders (APS) from Parkinson's disease (PD) remains challenging due to overlapping clinical features, yet accurate differentiation is critical for prognosis and treatment. Here, we employed multimodel diffusion MRI (dMRI) analysis to characterize microstructural alterations across corticobasal syndrome (CBS), progressive supranuclear palsy-Richardson syndrome (PSP-RS), and PD, with the aim of identifying which dMRI model and regional metrics show the strongest group-level separation. We analyzed 25 CBS, 42 PSP-RS, and 21 PD participants compared to 35 age and sex-matched controls. Using a clinically feasible 3-shell high angular resolution diffusion imaging (HARDI) protocol, we applied 11 metrics from five complementary dMRI models-diffusion tensor imaging (DTI), free-water-eliminated model of DTI (FWE), neurite orientation dispersion and density imaging (NODDI), tissue-weighted NODDI, and fixel density (FD) in fixel-based analysis (FBA)-to comprehensively assess regional white and gray matter integrity. Group differentiation was quantified using covariate-adjusted Cohen's d effect sizes and spearman correlations were assessed between dMRI metrics and clinical scales. Distinct microstructural signatures were observed across disorders, and the sensitivity of the dMRI models differed. In group contrasts, DTI and NODDI-derived metrics consistently captured the strongest effects in midbrain and peduncular pathways for PSP-RS, whereas precentral and corticospinal alterations in CBS were most prominent using NODDI and FBA measures. Free-water-corrected metrics showed attenuated group differences. Across clinical-diffusion analyses, NODDI metrics exhibited the most robust associations with disease severity, while DTI and FWE measures detected more limited, regionally constrained effects. Together, these findings highlight complementary yet distinct sensitivities of tensor, free-water, multicompartment, and fixel-based models to APS-related neurodegeneration.
Indexed as
Identifiers
42495865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.